INTRODUCTION:
Abdominally-based tissue has become the preferred technique for many women with breast cancer who are underdoing a mastectomy and do not desire implant-based reconstruction. However, the additional abdominal dissection results in increased pain post-operatively, requiring additional narcotic usage. It has been our mission to improve pain control following this reconstruction with the aims of facilitatating patients' recovery while decreasing narcotic usage, hospital stays and overall treatment costs. The transversus abdominis plane (TAP) block uses a local anesthetic to block the nerves supplying sensation to abdominal wall. Bupivacaine is the most commonly used anesthetic and can be injected plain or as a newer liposomal formula (Exparel®), which has sustained release and lasts three to four days. It is not currently known if either of these delivery methods provides a better pain relief.
METHODS:
IRB approval was granted to recruit women undergoing mastectomy with abdominalbased tissue reconstruction to be randomized to one of two study groups: a Transversus Abdominis Plane (TAP) block performed with either bupivacaine or liposome bound bupivacaine (Exparel®), a sustained relief pain medication. A retrospective control cohort consisting of six consecutive previously reconstructed patients who did not receive a TAP block were also identified. Pain was assessed using a subjective 1-5 pain scale, both at rest and after coughing, an abdominal specific assessment. Pain, nausea, emesis and activity were assessed at six, twelve, twenty-four, thirty-six and seventy-two hours. Total narcotic usage was calculated for hospital stay.
RESULTS:
From 2016, a total of sixteen patients have been enrolled: Exparel® (eight) and bupivacaine (eight). Patients who received Exparel® had a shorter average length of hospital stay as compared to the bupivacaine and control groups (4, 4.6 and 4.8 days). The Exparel® group demonstrated better sustained subjective pain control across time points both at baseline and during coughing. Oral, intravenous, and total narcotic usages (mg/body weight/day) were significantly less in the Exparel® group compared to the bupivacaine and control groups.
CONCLUSION:
Our preliminary results suggest that delivering Exparel® via a TAP block in abdominal-based breast reconstruction can result in decreased hospital stays and narcotic usage with improved pain control. 
Post-Operative

METHODS:
Randomized controlled trial comparing pain control following alloplastic breast reconstruction with muscle relaxer Cyclobenzaprine (intervention group) versus pain control following alloplastic breast reconstruction without muscle relaxer (control group). Patients met inclusion criteria and agreed to participate were included. Consent forms in both English and French languages were provided. The patients were randomly assigned to either group. Total of thirty patients participated in the study, fifteen patients in each group. Outcomes measured include, patient reported visual analog scale (VAS) pain scores day 1, 2 and 3, and the total number of narcotic pills taken within the 1 st three days at home following discharge from the hospital were recorded and subjected to the mean and standard deviation. Student T test was used for comparison; multiple and single linear regression was used to assess different factors on the outcome. A p value <0.05 is considered statistically significant.
RESULTS:
No significant difference has been noted. For the intervention group, mean pain score for 3 days after discharge was 5.67 (SD 6.89), while the control group had a mean of 6.73 (SD 3.99) (p = 0.61). As for the number of pills, for the intervention group mean was 8.00 (SD 4.74), while the control group had a mean of 9.33 (SD 7.05) (p = 0.55).
CONCLUSION:
There is no significance in pain score and number of narcotic pills when using the muscle relaxer cyclobenzaprine as an adjunct for pain control following alloplastic breast reconstruction. 
Intraoperative Pectoral Blocks Reduce
INTRODUCTION:
In response to a growing opioid crisis, there is an increased focus on reducing opioid consumption perioperatively. Pectoral nerve blocks (Pecs blocks) have previously been shown to successfully manage postoperative pain in mastectomy patients, decreasing perioperative opioid consumption and postoperative nausea. Over the past several years, we have begun incorporating Pecs blocks into our routine breast surgeries including reduction mammoplasty. The purpose of this study is to examine the impact of Pecs blocks on opioid consumption and antiemetic requirement in reduction mammoplasty patients.
METHODS:
We performed a retrospective review of all patients who underwent reduction mammoplasty between 2014-2016. All Pecs blocks were performed with ropivacaine under ultrasound guidance by the anesthesia team after induction of general anesthesia, but prior to the start of the operation. Demographics, operative details, opioid and antiemetic use, and complications were recorded. Opioid consumption was converted to a standardized oral morphine equivalence (OME) value for comparison. Outcomes of patients who received Pecs blocks were compared against those who did not.
RESULTS:
Seventy patients underwent reduction mammoplasty by four different attending plastic surgeons at our institution. Twenty-nine patients received Pecs blocks in addition to general anesthesia, while 41 patients received only general anesthesia without a Pecs block. These groups were similar with respect to age, BMI, average breast tissue resection, and follow up time. Performing the Pecs block added approximately 10 minutes of anesthesia time to the patients' case. Notably, intraoperative morphine consumption was significantly lower (85.03 vs 105.44, p = 0.01) in the Pecs block group. Additionally, OME for the first twelve hours following surgery remained slightly lower in the pectoral group (47.07 vs 49.72, p = 0.76), however did not reach significance. PACU antiemetic requirement also trended lower in the pectoral block group with 17.24% of block patients receiving antiemetics vs 24.39% of patients who did not receive a block (p = 0.47). This trend continued through the first twelve hours following surgery (34.48% vs 43.59%, p = 0.45). There were no complications related to the administration of the Pecs blocks.
CONCLUSION:
Pectoral nerve blocks provide a safe and effective means of perioperative pain control in breast reduction mammoplasty patients. Administration did not substantially increase anesthesia time but did significantly reduce the need for intraoperative opioid analgesia.
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